Anne Li August 12th, 2017 anne2001.li@gmail.com
An experimental immuno-oncology treatment will move into early phase clinical trials for patients with advanced solid tumours, including lung cancers, under a collaboration agreement between Cancer Research UK and Biotecnol Limited. Cancer Research UK will support the early clinical development of the company’s promising first-in-class Fdrug called Tb535H. The drug is the first to emerge from Biotecnol’s novel antibody development platform, Trisoma®. It is directed against the 5T4/WAIF1 tumour antigen, a protein found on many different solid tumours and is thought to contribute to the spread of cancer cells.
See original article at: https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2017-08-10-cancer-research-uk-and-biotecnol-to-trial-new-immuno-oncology-treatment-for-advanced-tumours